Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDYL2 | Q8N8U2 | 3/20 | 0.45 |
| ▸ | CDYL | Q9Y232 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TNKS | O95271 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.42 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.42 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.42 |
| ▸ | PARP16 | Q8N5Y8 | 1/20 | 0.42 |
| ▸ | PARP12 | Q9H0J9 | 1/20 | 0.42 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.42 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.42 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.42 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.42 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.42 |
| ▸ | CBX7 | O95931 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14564425 | 0.87 | L3MBTL1 (0.46) | CDYL2CDYLGAAPARP10ALDH1A1 | |
| SCHEMBL14564387 | 0.83 | ALDH1A1 (0.57) | GAAALDH1A1LMNAPOLBSMN1; SMN2 | |
| SCHEMBL2361576 | 0.82 | CDYL2 (0.45) | CDYL2CDYLALDH1A1POLBCBX7 | |
| SCHEMBL2360782 | 0.82 | NPY5R (0.47) | CDYL2CDYLALDH1A1PARP15TNKS2 | |
| SCHEMBL2407440 | 0.82 | SIGMAR1 (0.50) | CDYL2CDYLGAAALDH1A1POLB | |
| SCHEMBL2332474 | 0.78 | L3MBTL1 (0.60) | GAAALDH1A1POLBSMN1; SMN2TDP1 | |
| SCHEMBL2403057 | 0.78 | CDYL2 (0.64) | CDYL2CDYLALDH1A1LMNAPOLB | |
| SCHEMBL17067778 | 0.73 | L3MBTL1 (0.68) | GAAALDH1A1LMNAPOLBSMN1; SMN2 | |
| SCHEMBL11161652 | 0.73 | TMEM97 (0.54) | SIGMAR1 | |
| SCHEMBL22766838 | 0.73 | PARP10 (0.46) | PARP10ALDH1A1POLBTNKSPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230277501-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY | 2023-09-07 | — | — | US | disclosed |
| US-20230033195-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY | 2023-02-02 | — | — | US | disclosed |
| US-20220265685-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY | 2022-08-25 | — | — | US | disclosed |
| US-11160785-B2 | Methods and compositions for improving cognitive function | AGENEBIO INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-20210244709-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY | 2021-08-12 | — | — | US | disclosed |
| EP-3827820-A1 | BRIVARACETAM FOR IMPROVING COGNITIVE FUNCTION | The Johns Hopkins University (US) | 2021-06-02 | — | — | EP | disclosed |
| US-10806717-B2 | Methods and compositions for improving cognitive function | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-10-20 | — | — | US | disclosed |
| US-10624875-B2 | Methods and compositions for treating schizophrenia | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-04-21 | — | — | US | disclosed |
| EP-3610890-A1 | METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA | The Johns Hopkins University (US) | 2020-02-19 | — | — | EP | disclosed |
| US-10154988-B2 | Methods and compositions for treating schizophrenia | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-12-18 | — | — | US | disclosed |
| US-20110212928-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-09-01 | — | — | US | disclosed |
| WO-2011100373-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-08-18 | — | — | WO | disclosed |
| US-20100222326-A1 | New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders | UCB PHARMA, S.A. (BE) | 2010-09-02 | — | — | US | disclosed |
| US-20100222326-A1 | New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders | UCB PHARMA, S.A. (BE) | 2010-09-02 | — | — | US | disclosed |
| US-20100222326-A1 | New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders | UCB PHARMA, S.A. (BE) | 2010-09-02 | — | — | US | disclosed |
| EP-2152262-A2 | NEW HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | UCB Pharma, S.A. (BE) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008132139-A2 | NEW HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | UCB PHARMA S.A. (BE) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008132142-A2 | NEW HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | UCB PHARMA S.A. (BE) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008132139-A2 | NEW HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | UCB PHARMA S.A. (BE) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008132142-A2 | NEW HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | UCB PHARMA S.A. (BE) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10806717-B2 | Methods and compositions for improving cognitive function | GRIN2A, CHRNA2, SYNGR2 | CDYL2 339/4885CDYL 1611/4885GAA 375/4885 |
| US-10154988-B2 | Methods and compositions for treating schizophrenia | RAB2A, SYNGR2, GRIN2A | CDYL2 971/4885CDYL 2385/4885GAA 1187/4885 |
| US-20210244709-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | GRIN2A, CHRNA2, SYNGR2 | CDYL2 339/4885CDYL 1611/4885GAA 375/4885 |
| US-11160785-B2 | Methods and compositions for improving cognitive function | BACE2, BACE1, GRIN2A | CDYL2 1832/4885CDYL 3482/4885GAA 89/4885 |
| US-10624875-B2 | Methods and compositions for treating schizophrenia | RAB2A, SYNGR2, GRIN2A | CDYL2 478/4885CDYL 1285/4885GAA 1305/4885 |
| US-20100222326-A1 | New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders | CNR2, CNR1, SLC18A2 | CDYL2 2678/4885CDYL 2832/4885GAA 638/4885 |
| US-20230277501-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | GRIN2A, CHRNA2, SYNGR2 | CDYL2 339/4885CDYL 1611/4885GAA 375/4885 |
| US-20220265685-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | BACE1, BACE2, ACHE | CDYL2 3071/4885CDYL 4362/4885GAA 545/4885 |
| US-20110212928-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | BACE1, BACE2, ACHE | CDYL2 3071/4885CDYL 4362/4885GAA 545/4885 |
| US-20230033195-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | GRIN2D, GRIN2A, SLC18A2 | CDYL2 2361/4885CDYL 4273/4885GAA 594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.